Japan Lifeline plans to make US-based Cross Vascular, which develops high-frequency systems for cardiac surgery, a subsidiary. The acquisition price is approximately ¥977 million, the transaction date is 30 September 2026, and all shares will be acquired through its local subsidiary.
Japan Lifeline disclosed plans to make US-based Cross Vascular, Inc., which develops and manufactures high-frequency systems for transseptal puncture, a subsidiary and strengthen its business base in overseas markets, particularly the United States. All shares of Cross Vascular are scheduled to be acquired through local subsidiary JLL Med USA Inc.
Cross Vascular offers products that have received FDA approval and holds 4 USPTO patents as part of its intellectual property portfolio. This will expand its business base in high-frequency systems for the cardiovascular field.
The acquisition price is approximately ¥977 million, and the transaction date is 30 September 2026. For the fiscal year ended December 2025, Cross Vascular recorded an operating loss of approximately ¥314,000 and net assets of approximately ¥486 million.
Through the acquisition, Japan Lifeline is expected to strengthen its overseas operations and pursue expansion in the US market.